Biotech Startups

Alivexis is a drug discovery company that develops small molecule therapeutics targeting cancer, immune-inflammatory conditions, and rare diseases, leveraging computational platforms and disease biology expertise across operations in Japan and the US.

5 investors

ThinkCyte develops diagnostic devices and cellular analysis platforms using imaging flow cytometry and microfluidics technology. The company serves research institutions, clinical laboratories, and biopharmaceutical companies in the life sciences and diagnostic tools sector.

5 investors

Modalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development. It operates in the biotechnology sector.

5 investors

RegiMMune is a biotech company with an investor relations section providing financial reports and corporate governance documents.

4 investors

3T Biosciences develops TCR-based immunotherapies for cancer using a proprietary platform that combines machine-learning algorithms with immunological research to identify and validate T cell receptor targets. The company creates therapeutic treatments targeting cancer and other difficult-to-treat diseases.

4 investors

Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition. It operates in the biotechnology and pharmaceutical sector.

4 investors

Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs that inhibit hunger to treat metabolic diseases. Its lead compound, ARD-101, is an oral investigational drug for hunger-associated rare diseases that activates bitter taste receptors in the gut to trigger satiety signals, with potential applications in hyperphagia and obesity.

4 investors

AceCann cultivates, processes, and extracts medical cannabis products aimed at the European market. The company produces its products to pharmaceutical standards for use in the medical cannabis sector.

4 investors

Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.

4 investors

Acticor Biotech develops Glenzocimab, a therapeutic candidate targeting GPVI for treating acute ischemic stroke and STEMI. The company is focused on cardiovascular and cerebrovascular indications.

4 investors

Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a small-molecule GSK-3β inhibitor designed to treat difficult-to-treat cancers including pancreatic, melanoma, lung, and pediatric cancers through intravenous injection and oral tablet formulations. The company is advancing elraglusib in multiple clinical trials, with Phase 2 data in metastatic pancreatic cancer showing improved overall survival when combined with standard chemotherapy.

4 investors

4 investors

Adagene is a clinical-stage immunotherapy company that uses computational biology and artificial intelligence to discover and design therapeutic antibodies for cancer treatment. The company's platform generates novel antibodies aimed at improving safety and efficacy in precision-guided antibody-drug conjugates and other therapeutic approaches.

4 investors

ADC Therapeutics is a biopharmaceutical company that develops antibody drug conjugates and other therapies focused on hematology and oncology. It operates in the biotech and pharmaceutical industry.

4 investors

Adipo develops investigational therapeutics that promote weight loss by activating brown fat to increase energy expenditure, offering an alternative to appetite-suppressing drugs like GLP-1s. The company targets people seeking weight management solutions beyond diet and calorie restriction.

4 investors

Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.

4 investors

Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma. The company focuses on respiratory care for patients with these conditions.

4 investors

Affini-T Therapeutics develops TCR-based immunotherapies aimed at treating solid tumors, using two complementary therapeutic modalities. The company operates in the biotech and cancer immunotherapy space.

4 investors

Affinivax was a clinical-stage biopharmaceutical company that developed next-generation pneumococcal vaccines using its proprietary Multiple Antigen Presenting System (MAPS) platform technology. The company has been acquired by GSK.

4 investors

Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.

4 investors

Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease. The company's approach is grounded in cellular metabolism research and involves close collaboration with patients and clinical partners.

4 investors

Ahammune develops therapeutic treatments for chronic skin diseases with unmet medical need. The company aims to address dermatological disorders through scientific innovation and comprehensive treatment strategies.

4 investors

AIVIVO develops drug discovery solutions at the organism level, focusing on accelerating pharmaceutical development processes.

4 investors

AICure is an AI-powered medication adherence platform for life sciences organizations that uses computer vision and machine learning to verify patient medication adherence and capture real-time behavioral data to improve clinical trial outcomes and patient engagement. The platform serves pharmaceutical companies, clinical trial operators, and healthcare organizations seeking objective insights into medication compliance without wearables or invasive hardware.

4 investors